JSR Corporation
B2B specialty-materials supplier: designs, qualifies and manufactures photoresists, CMP, display and packaging materials sold into leading-edge chip foundries/IDMs; revenue is recurring per-node consumable volume plus multi-year co-development lock-in. Now 100% owned by JIC (Japan Investment Corporation).
JSR is a formerly-public company taken private (not venture-backed), so the trail is the take-private sequence rather than VC rounds. The pre-deal reference point is estimated from the disclosed ~34% takeover premium; the agreed and completed points reflect the JPY4,350/share (~JPY900-909B) deal value, with the USD figure sensitive to the yen rate used (~JPY143-150/USD).
Earnings, margins, COGS & capex
FY ending Mar 2025 was a deliberate 'big bath' under new JIC ownership: group revenue ~JPY409B (~$2.7B) with ~JPY19B group operating profit, but a net loss of ~JPY217.5B driven by ~JPY157.6B of impairments (largely Life Sciences goodwill/intangibles ahead of divestiture) plus ~JPY40.5B of post-TOB purchase-price-allocation amortization. The core Semiconductor Materials business grew ~30% and set a profit record. Through 2025-2026 JSR sold or agreed to sell its life-sciences portfolio (IVD/IVDM to Tokuyama, completed Oct 1 2025; Crown Bioscience to Adicon, agreed Nov 2025 and closing mid-2026; bioprocess materials), largely completing a pivot to a leading-edge digital-solutions/semiconductor-materials pure-play. Elastomers were already carved out earlier (ENEOS Materials; emulsions/fine chemicals to Resonac and others).
Revenue trend
Margins
structurally low on legacy drag; improving as portfolio narrows to semiconductors
one-off - impairment-driven big bath, not operating cash loss
rising on EUV/AI demand
COGS structure
Raw materials are specialty monomers, polymers, PAGs/photoacid generators, metal-oxide precursors (Inpria), and high-purity solvents (e.g. PGMEA); cost base is chemistry + rigorous purification/QC rather than commodity feedstock. Exact COGS breakdown not disclosed post-delisting.
Capex
Growth capex centered on advanced-lithography capacity, including JSR's first Taiwan photoresist plant (JV formed ~2026 in Yunlin County, targeted online ~2028) to co-develop/localize EUV materials for TSMC; specific capex figure not disclosed post-delisting.
Latest earnings
not applicable (no consensus / no public listing)
Management target: core operating profit of ~JPY100B by 2030, driven by semiconductor materials; JIC targets a re-listing in ~5-7 years
- Global photoresist share
- ~19% by sales (2025; a top-2 global maker per Nikkei; earlier ~27%/'#1' figures are stale)
- SEMI segment revenue growth FY3/25
- ~+30% YoY
- Impairment (big bath) FY3/25
- ~JPY157.6B, mostly Life Sciences
- Take-private price / value
- JPY4,350/share; ~JPY900B (~$6.3B)
Growth drivers
- AI/data-center chip demand pulling leading-edge (3nm/2nm) wafer starts and EUV layer counts
- EUV photoresist adoption - more EUV layers per node multiplies resist consumption
- Metal-oxide resist (MOR) via Inpria for high-NA EUV and next-gen DRAM patterning
- Geographic localization near foundries (planned Taiwan plant to supply TSMC) deepening customer lock-in
- Portfolio focus — proceeds and management attention redirected from divested life-sciences/elastomers into semiconductors
- JIC-sponsored industry consolidation to build a larger Japanese materials champion ahead of a targeted re-listing
Bull & bear
A cleaned-up, state-backed pure-play sitting on one of the most defensible chokepoints in the AI supply chain - leading-edge photoresist - with a credible path to doubling core profit and re-listing into an AI-materials premium.
- Holds ~19% of the photoresist market (a top-2 global maker) and a leading position in the hardest-to-substitute high-end EUV resist at 3nm/2nm - the AI-accelerator nodes consume JSR chemistry
- Life-sciences/elastomer divestitures remove loss-making drag; remaining SEMI business already grows ~30% and set a profit record
- Inpria metal-oxide resist positions JSR for high-NA EUV and next-gen DRAM patterning - a technology optionality peers lack
- JIC patient capital funds capacity (planned Taiwan plant for TSMC) and consolidation without public-market short-termism; JPY100B 2030 core-profit target implies a large earnings step-up
- Re-listing in 5-7 years offers a valuation re-rating catalyst as a focused EUV-materials champion
A cyclical, capital-intensive materials business dressed as a growth story - carrying acquisition leverage, government-ownership overhang, and formidable Japanese rivals, with the big bath revealing how thin group economics really are outside the crown-jewel segment.
- The JPY217.5B net loss and JPY157.6B impairment show much of the old portfolio destroyed value; the SEMI jewel must now carry the whole company
- Group operating margin ~4.7% is unimpressive, and group core operating profit fell sharply on PPA amortization; the standalone-SEMI margin isn't independently disclosed, obscuring true profitability
- Tokyo Ohka Kogyo and Shin-Etsu are peers, not also-rans, in EUV resist - JSR is roughly co-leader, not runaway #1, so share and pricing are contestable
- Semiconductor capex is deeply cyclical; an AI-capex digestion phase would hit resist volumes fast
- State ownership + take-private leverage create governance/exit uncertainty; a re-listing is years out and market-dependent
- Korea/China materials-localization and export-control crosscurrents pressure the non-leading-edge base
What it is worth
Take-private transaction anchor + specialty-materials peer read-through (private company; no live market price)
~$4-6B
semiconductor downcycle, contested EUV share, and leverage/governance overhang cap value below the deal price until a proven, profitable pure-play emerges
~$6-8B
broadly the take-private value plus modest re-rating as focus and SEMI growth offset cyclicality and leverage
~$9-12B+ on a successful re-listing as an AI-materials champion - SEMI margin expansion + JIC-led consolidation + high-NA/MOR optionality earning a premium multiple
JIC's 2024 take-private valued JSR at ~JPY900B (~$6.3B) at JPY4,350/share. As a now-focused EUV/AI-materials pure-play (post life-sciences/elastomer exits), a re-rating toward premium specialty-materials multiples (TOK, Shin-Etsu, Entegris) is the core thesis into an eventual re-listing. Group margins remain low, so value hinges on the semiconductor-materials segment's earnings trajectory toward the JPY100B 2030 core-profit target.
SWOT
Strengths
- A top-2 global photoresist maker (~19% share by sales, 2025) and a leader in high-end EUV resist; part of the Japanese cluster that supplies the large majority of frontier EUV chemistry
- Deep, sticky co-development relationships with TSMC, Samsung, Intel, SK hynix on leading-edge nodes
- Inpria metal-oxide-resist IP - differentiated position for high-NA EUV and next-gen DRAM
- Government backing via JIC provides patient capital and consolidation firepower
- Now a focused semiconductor-materials pure-play after divesting life sciences and elastomers
Weaknesses
- FY3/25 net loss (~JPY217.5B) and heavy impairments expose weak legacy-segment economics
- Group operating margin (~4.7%) still low versus best-in-class specialty-materials peers
- Revenue concentration in a handful of leading-edge chip customers
- Reduced transparency and market discipline as a private, state-owned entity
- Acquisition leverage from the take-private sits above the operating business
Opportunities
- AI-driven leading-edge capex supercycle raising EUV layers and resist volume per wafer
- High-NA EUV and metal-oxide resists as a step-change TAM expansion
- Localized supply for TSMC (planned Taiwan plant) and potential US/Japan fab build-outs
- JIC-led consolidation to acquire adjacent Japanese materials assets and re-list at a premium
- Cross-licensing/partnerships (Lam Research, Entegris) broadening ecosystem reach
Threats
- Semiconductor capex cyclicality and inventory corrections
- Aggressive competition from Tokyo Ohka Kogyo and Shin-Etsu in EUV chemistry
- Korea/China localization drives (Dongjin Semichem, domestic Chinese resist programs) eroding non-leading-edge share
- Geopolitical/export-control friction affecting materials flows
- Government ownership overhang complicating governance, M&A optics and eventual exit pricing
Moats, dependencies & bottlenecks
Moats
A resist is validated into a specific process node over years; switching risks yield - customers rarely re-qualify a rival mid-node.
Chemically-amplified + Inpria metal-oxide resists at the frontier; sustained via heavy R&D and foundry co-development.
Japanese makers supply the large majority of high-end EUV resist; JSR benefits from the ecosystem, purity supply chain and JIC backing.
Embedded with TSMC/Samsung/Intel/SK hynix roadmaps; planned Taiwan localization deepens it.
Dependencies
Resist volume tracks leading-edge wafer starts and EUV layer counts.
Resist demand is downstream of EUV lithography adoption pace.
Ownership/funding Sole owner; funds capacity and consolidation but controls governance and exit timing.
PGMEA, specialty monomers, metal precursors) Ultra-high-purity inputs; contamination is a yield killer.
Current growth is AI-capex-led and therefore cyclical.
Advantages
- Top-2 global photoresist share (~19% by sales, 2025) and a leading high-end EUV position
- Inpria metal-oxide-resist differentiation for high-NA EUV and DRAM
- Patient state capital (JIC) enabling counter-cyclical investment and M&A
- Focused pure-play profile after divesting life sciences and elastomers
- Planned localized supply for TSMC (Taiwan) reinforcing lock-in
Weaknesses
- Low group operating margin (~4.7%) and a large FY3/25 net loss
- Standalone semiconductor-segment profitability not independently disclosed
- Reduced transparency as a private, government-owned company
- Take-private leverage and years-out, market-dependent re-listing
- Contestable EUV share versus TOK and Shin-Etsu (roughly co-leader, not runaway #1)
Bottlenecks
- Semiconductor capex cyclicality - a downcycle compresses resist volumes quickly
- Customer concentration in a few leading-edge fabs
- Post-big-bath restructuring execution and integration under new ownership
- Elevated near-term capex (planned Taiwan plant) before it contributes revenue (~2028 target)
- Acquisition leverage at the holdco and government-ownership governance overhang
- Export-control / geopolitical friction on materials flows
Top signals & trends
Top signals
Core business inflecting on AI/EUV demand.
Localization would deepen leading-edge lock-in once it ramps.
Sharpens focus, removes loss-making drag.
Broadens dry/MOR resist ecosystem reach.
Reveals weak legacy economics; a kitchen-sink year.
No near-term liquidity or price-discovery catalyst.
Trends
More EUV layers per node multiplies resist consumption.
TAM expansion and a technology moat where JSR/Inpria are positioned.
Favors incumbents that can co-locate and qualify locally.
Erodes mature-node share over time.
Scale upside but integration and governance risk.
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
High-purity solvent/monomer & specialty-chemical suppliers Ultra-high-purity PGMEA, monomers, PAGs and metal precursors feeding resist synthesis
In-house metal-oxide-resist technology and precursor know-how for EUV/high-NA
Leading-edge foundry; anchor EUV-resist customer, planned Taiwan plant sited to supply it
Foundry + memory; leading-edge resist customer
Leading-edge logic + foundry ambitions; EUV/high-NA collaboration
DRAM/NAND; MOR co-development for next-gen DRAM patterning
US memory maker consuming advanced lithography materials
Closest EUV-resist rival; co-leader in chemically-amplified EUV photoresist
Materials giant with strong photoresist and broad semiconductor-materials portfolio
Advanced photoresist and process chemicals; deep foundry ties
Photoresist and semiconductor/display materials competitor
US electronic-materials competitor in photoresists and lithography chemicals
Global electronic-materials rival across resists and specialty chemistry
Korean resist supplier; spearheads Korea/China localization at mature nodes